Prevalence of Fabry disease among patients with hypertrophic cardiomyopathy, dilated cardiomyopathy and left ventricular hypertrophy with proteinuria

Prevalence of Fabry disease among patients with hypertrophic cardiomyopathy, dilated cardiomyopathy and left ventricular hypertrophy with proteinuria - Prevalence of Fabry disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015821

Enrollment

500

Registered

2014-12-03

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry disease

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Participants are inpatients and outpatients of the Ehime University Hospital. Patients with hypertrophic cardiomyopathy, dilated cardiomyopathy and left ventricular hypertrophy(septal thickness or posterior wall thickness is 13 mm and over) with proteinuria(dipstick proteinuria of 1+ and over). Patients gave written informed consent.

Exclusion criteria

Exclusion criteria: Patients judged inappropriate for the study by their physicians.

Design outcomes

Primary

Measure	Time frame
Prevalence of Fabry disease	—

Countries

Japan

Contacts

Public ContactKen-ichi Miyoshi

Ehime University Graduate School of Medicine Department of Cardiology, Pulmonology, Hypertension and Nephrology

miyoken@m.ehime-u.ac.jp089-960-5303

Outcome results